dual agonist glp 1 Effects, working principles and target tissues of agonists Effects of tirzepatide, a dual
Description
Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity

Discover Now!

BCBS dropped GLP-1 weight loss drug coverage across multiple states

Research on the experimental drug petrelintide suggests it is much less likely to cause nausea and vomiting than GLP-1 drugs, but the pace of weight loss is more moderate.

On the other hand, TIIDM is characterized by an imbalance between insulin levels and insulin sensitivity, resulting in persistent hyperglycemia

The magnitude of the benefits of GLP-1RA and SGLT-2 inhibitors on MACE are similar, ranging from 12 to 14% reduction of risk, but only GLP-1RA may reduce the risk of stroke